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ABSTRACT 
Hereditary hemoglobinopathies, mainly sickle cell disease (SCD) and β-thalassemia, 
contribute to iron overload through hemolysis and hemoglobin (Hb) degradation. Hemin (Fe3+-
heme), released from the extracellular Hb, is identified as a critical player in 
hemoglobinopathies. Heme and iron released from hemoglobin during hemoglobinopathies lead 
to reactive oxygen species formation (ROS) and oxidant injury to cells and tissues, including the 
vascular endothelium. Pulmonary hypertension has been recognized as a serious complication in 
SCD and lung microvasculature appears to be a target to iron-induced lung microvascular 
endothelial dysfunction contributing to pulmonary hypertension in SCD. Currently available iron 
chelation therapies for the protection against iron-induced stress in SCD patients are limited and 
not efficacious. Therefore, here we hypothesized that iron overload would cause reactive oxygen 
species (ROS) generation and oxidative stress in SCD crisis triggering the redox-regulated 
activation of the membrane phospholipid-hydrolyzing and cellular lipid signaling enzyme, 
phospholipase D (PLD) in lung microvascular endothelium, which could be the underlying 
mechanism(s) of pulmonary hypertension in SCD patients. In our current investigation, we 
established the oxidant and thiol-redox mediation of iron-induced (hemin) cytotoxicity through 
PLD-mediated lipid signaling in the bovine lung microvascular endothelial cell (BLMVEC) 
model in vitro. Additionally, our study revealed that hemin caused cytotoxicity through ROS 
generation, oxidative stress, depletion of glutathione (GSH) redox status, membrane lipid 
peroxidation, and phospholipase D (PLD) activation, formation of PLD-generated bioactive lipid 
mediator, phosphatidic acid (PA), and lipid signaling in BLMVECs. The PLD-specific 
pharmacological inhibitor,	   5-fluoro-2-indolyl des-chlorohalopemide hydrochloride hydrate 
(FIPI), not only attenuated hemin-induced PLD activation but also protected against cytotoxicity 
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of hemin in BLMVECs suggesting the regulatory role of PLD and the PLD-generated bioactive 
lipid, PA in cytotoxicity of hemin in endothelial cells (ECs). Furthermore, our current study 
demonstrated that N,N'-bis-2-mercaptoethyl isophthalamide (NBMI), a novel synthetic, non-
toxic, and lipophilic thiol-redox heavy metal chelator and antioxidant drug, offered a greater 
efficacy in attenuating the hemin-induced oxidative stress and PLD activation and protection 
against cytotoxicity of hemin in lung microvascular ECs as compared to the currently used iron 
and trace metal chelating drugs and thiol-protectants, thus offering promise for the treatment of 
iron overload and associated vascular EC injury during hemoglobinopathies including SCD. 
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INTRODUCTION 
Sickle cell disease (SCD) and β-thalassemia are conditions in which red blood cells 
(RBCs) contain abnormal hemoglobin (Hb), which results to the inability to effectively transport 
oxygen and thus leads to anemia in patients. SCD is caused by a substitution of valine for 
glutamic acid at the β-6 position in the Hb β-chain. This substitution results in production of 
hemoglobin S (HbS), which polymerizes under deoxygenated conditions (Jaffe and Neurmann, 
1964). Production of hemoglobin C (HbC) is the result of a mutation at the same β-6 position 
that leads to intraerythrocytic crystal formation under oxygenated conditions (Hirsch et al., 
1985). As a result of the abnormal Hb produced from these mutations, RBCs are degraded 
through a process known as Hb autoxidation. Under normal physiological conditions, only about 
3% of the total body hemoglobin undergoes autoxidation every day (Jaffe and Neurmann, 1964). 
However, since both HbS and HbC are less stable than normal adult hemoglobin (HbA), Hb 
autoxidation occurs at an accelerated rate in SCD and thalassemia patients.  
 
During Hb autoxidation (degradation), hemoglobin (Hb) bursts from RBCs (hemolysis) 
releasing naked Hb devoid of its antioxidant counterparts that are normally available within the 
RBC. Therefore, the release of Hb can cause severe oxidative damage in the vasculature and in 
exposed tissues (Balla et al., 2007). The process of Hb autoxidation produces toxic degradation 
products such as hemin (ferric protoporphyrin-IX or Fe3+-heme) (Fig. 1), methemoglobin 
(metHb), and superoxide anion (O2.-). To neutralize Hb and its reactive degradation products, 
specialized plasma scavenger proteins typically sequester the toxic compounds and transport 
them to isolated compartments where heme-oxygenases can metabolize hemin into less toxic 
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metabolites. The presence of native thiol-redox antioxidants (glutathione, GSH) (Fig. 2) and 
antioxidant enzymes (catalase, superoxide dismutase, and GSH peroxidase) also assist in the 
attenuation of hemin-induced oxidant toxicity by neutralizing superoxide and metHb-induced 
toxicity. However, when these clearance and detoxifying systems are overwhelmed by large 
amounts of intravascular hemolysis and autoxidation (due to the presence of destabilizing 
hemoglobin mutations or chain imbalance as in the case of SCD or β-thalassemia), the excessive 
amount of hemin produced is able to induce oxidative stress and oxidant injury in cells and 
tissues (Balla et al., 2007).  
 
In addition, the escalated rate of Hb degradation through Hb autoxidation in SCD patients 
results in an accumulation of iron (Fe, released during Hb autoxidation) in cell membranes of 
pathological RBCs and surrounding tissues (Shinar and Rachmilewitz, 1990). Iron is one of the 
most important trace elements (metals) in the biological systems, serving the essential role in 
mammalian systems as an important element in several enzymatic reactions while also acting as 
a crucial element of hemoglobin (Hb) acting as an oxygen carrier for cellular respiration and 
energy generation. However, iron is also an established Fenton reagent that can conditionally 
cause severe damage to membrane lipids through formation of ROS leading to lipid 
peroxidation, which results in adverse effects to cells including cytotoxicity and death. Blood 
vessels are especially vulnerable to oxidative stress and oxidant injury caused by hemin-overload 
in SCD (Dominik et al., 2013). The vascular endothelium, the inner lining (monolayer) of the 
blood vessel, pivotal for the homeostasis of circulation, is also highly vulnerable to oxidative 
stress caused by iron overload in SCD (Shinar and Rachmilewitz, 1990). Additionally, iron-
induced oxidative stress has been established to cause vascular endothelial cell (EC) damage 
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through oxidant signaling and thiol-redox (GSH) dysregulation. Furthermore, oxidative stress 
and trace heavy metals have been shown to induce lipid signaling in the cellular membranes 
through the activation of membrane phospholipid-hydrolyzing enzymes including 
phospholipases A2 and D (PLA2 and PLD) (Mazerik et al., 2007; Secor et al., 2011; Patel et al., 
2011). Among the phospholipases, PLD is a ubiquitous enzyme present in mammalian cells 
including the lung vascular ECs (Parinandi et al., 2001). PLD catalyzes the hydrolysis of 
membrane phospholipids to form the bioactive signal lipid, phosphatidic acid (PA) which causes 
EC dysfunction including the lung vascular leak (Fig. 3) (Usatyuk et al., 2013). Also, we have 
shown that PLD in lung vascular ECs is activated by ROS, oxidants, and thiol-redox 
dysregulation (Patel et al., 2011; Parinandi et al., 1999).  Excessive Hb degradation and RBC 
hemolysis in SCD can cause vascular and organ dysfunction leading to adverse clinical effects 
such as hypertension, endothelial dysfunction, renal failure, or immune dysregulation. 
Pulmonary hypertension is one of the serious complications in SCD patients (Machado and 
Gladwin, 2005) but the underlying mechanisms are not thoroughly understood. ROS and 
oxidative stress have been shown to cause lung vascular endothelial damage leading to vascular 
leak (Usatyuk et al., 2013). However, the Hb degradation product, hemin-induced oxidant lipid 
signaling that is mediated by PLD has not been reported in the mammalian cellular models 
including the lung microvascular ECs. Hence, we hypothesized that iron overload would 
cause ROS generation and oxidative stress in SCD crisis triggering the redox-regulated 
activation of the membrane phospholipid-hydrolyzing and cellular lipid signaling enzyme, 
PLD in lung microvascular endothelium, which could be the underlying mechanism(s) of 
pulmonary hypertension in SCD patients.  
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In order to counteract iron overload encountered in SCD, several iron chelator drugs have 
been used to treat symptoms of iron toxicity and oxidative stress in SCD patients (Lucania et al., 
2011). However, the commonly used iron chelator drugs such as meso-dimercaptosuccinic acid 
(DMSA) and desferal (desferrioxamine) are water-soluble and administered at very high doses 
and may not reach the lipid-rich membranes which are the target sites of iron-induced oxidative 
stress (membrane lipid peroxidation). Desferal has also been shown to be toxic and not 
efficacious to protect against the iron overload in SCD (Galanello et al., 2012). Since the 
currently available water-soluble chelator drugs are either not effective or marginally effective, a 
highly efficacious iron chelator is needed to attenuate iron- and heme-Fe-induced oxidant 
damage in SCD patients. Recently we have reported that our novel and synthetic non-toxic lipid-
soluble thiol-redox heavy metal chelator and antioxidant drug N,N'-bis-2-mercaptoethyl 
isophthalamide (NBMI) (Fig. 2) attenuates oxidant- and heavy metal-induced PLD signaling and 
cytotoxicity in vascular ECs through stabilization of thiol-redox and attenuation of oxidative 
stress (Secor et al., 2011; Patel et al., 2011). Also, an effective and non-toxic lipophilic iron 
chelator is highly essential for therapeutic protection against the iron-induced oxidative stress 
and oxidant injury in the vascular endothelium of the SCD patients. Therefore, we also 
hypothesized that our novel lipid-soluble thiol-redox heavy metal chelator and antioxidant 
drug, NBMI, as opposed to the currently used water-soluble iron chelators (e.g. desferal), 
can reach the membrane lipid targets of lung vascular ECs (where iron tends to 
accumulate and cause oxidative stress and lipid signaling events), and thus might offer 
more effective protection against iron-induced oxidative damage to the lung vascular 
endothelium.  
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 In order to test our hypotheses, in the current study, we investigated the role that Fe3+-
heme (hemin) that arises from Hb degradation in mediating membrane lipid signaling through 
redox regulation in cultured bovine lung microvascular EC (BLMVEC) model to establish the 
role of PLD in lung EC dysfunction as a mechanism of pathogenesis of iron overload-driven 
pulmonary hypertension encountered in SCD complications. Furthermore, we also investigated 
efficacy of the novel thiol-redox heavy metal chelator and antioxidant drug in attenuating the 
hemin-induced oxidant PLD signaling and protecting against hemin cytotoxicity in BLMVECs. 
Our study revealed that hemin caused cytotoxicity through ROS generation, oxidative stress, 
depletion of glutathione (GSH) redox status, membrane lipid peroxidation, and phospholipase D 
(PLD) activation, formation of PLD-generated bioactive lipid mediator, phosphatidic acid (PA), 
and lipid signaling in BLMVECs. Also, our current study demonstrated that the novel thiol-
redox heavy metal chelator and antioxidant drug, NBMI, offered a greater efficacy in attenuating 
the hemin-induced oxidative stress and PLD activation and protection against hemin-induced 
cytotoxicity in BLMVECs in comparison with the commonly used iron and trace metal chelating 
drugs and thiol-protectants.  
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MATERIALS & METHODS 
Materials 
Bovine lung microvascular endothelial cells (BLMVECs) (passage 2) were purchased 
from Cell Applications Inc. (San Diego, CA). Phosphate-buffered saline (PBS) was obtained 
from Biofluids Inc (Rockville, Maryland). Minimal essential medium (MEM), nonessential 
amino acids, trypsin, FBS, penicillin/streptomycin, Dulbecco modified Eagle medium (DMEM) 
phosphate-free modified medium, tissue culture reagents, 3-[4,5-dimethylthiazol-2-yl]-2, 5-
diphenyl tetrazolium bromide reduction kit (MTT assay kit), lactate dehydrogenase cytotoxicity 
assay kit (LDH release assay kit), and analytical reagents of highest purity were all purchased 
from Sigma Chemical Co (St Louis, Missouri). Phosphatidylbutanol (PBt), fluorescent C6:0-18:1 
NBD-PA, 1-oleoyl-2-{6-[(7-nitro-2-1, 3-benzoxadiazol-4-yl) amino]hexanoyl}-sn-glycero-3-
phosphate (C18:2 PA), and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (C16:0-18:1 PA) were 
obtained from Avanti Polar Lipids (Alabaster, Alabama). [32P]orthophosphate (carrier-free) was 
obtained from New England Nuclear (Wilmington, Delaware). Bleomycin was obtained from 
Teva Parenteral Medicines (Irvine, California). Desferal was obtained from Calbiochem (San 
Diego, California). Polyclonal antibody raised against 4-hydroxy-2-nonenal (anti-HNE) was 
obtained from Enzo Life Sciences (Farmingdale, New York). Endothelial cell growth factor was 
obtained from Upstate Biotechnology (Lake Placid, New York). Antirabbit AlexaFluor 488-
conjugated antibody and 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI) were purchased 
13	  
	  
from Molecular Probes Invitrogen Co (Carlsbad, California). The novel lipophilic thiol-redox 
chelator and antioxidant drug and 5-fluoro-2-indolyl des-chlorohalopemide hydrochloride 
hydrate (FIPI) was prepared as described earlier (Secor et al., 2011; Patel et al., 2011).  
Glutathione (GSH) assay kit (GSH-Glo) was obtained from Promega Corporation (Madison, 
Wisconsin). All other reagents were obtained from the Sigma Chemical Company (St. Louis, 
MO). 
 
In Vitro Cell Culture 
BLMVECs were cultured in the minimum essential medium supplemented with 10% 
FBS, antibiotics, non-essential amino acids, and endothelial cell growth factor up to 90-100% 
confluence in 35-mm dishes (5 x 105 cells/dish) according to our published procedures (Secor et 
al., 2011; Patel et al., 2011). BLMVECs were used up to passage 16 for all the experiments. 
 
Lactate Dehydrogenase (LDH) Release Assay of Cytotoxicity  
BLMVECs were grown to 90-100% confluence in 24-well culture plates and treated with 
MEM alone, or MEM containing chosen concentrations of hemin and/or NBMI at varying time 
points.  At the end of the incubation period, the supernatant was removed, and the extent of LDH 
released was measured by spectrophotometric method according to the manufacturer’s 
recommendations (Sigma Chemical Co., St. Louis, MO) (Hagele et al., 2007; Patel et al., 2012).   
 
Cellular Morphology 
BLMVECs were grown in 12-well culture plates to 90-100% confluence. Following their 
exposure to the chosen concentrations of hemin and/or NBMI or other pharmacological agents at 
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different time points, the cells were examined under the microscope for morphological 
alterations as an index of cytotoxicity.  Images of cellular morphology were digitally captured 
using the Zeiss Axiovert S100 at 10x magnification (Hagele et al., 2007; Patel et al., 2012). 
 
Superoxide (O2.-) Measurement by DHE Fluorescence 
Generation of superoxide in BLMVECs was determined by DHE (dihydroethidium) 
fluorescence. BLMVECs grown in 35-mm dishes were treated with different concentrations of 
hemin and/or NBMI for 1 h. After treatment, the cells were washed once with warm PBS and 
incubated with DHE (5 µM) in warm PBS for 30 min. After incubation, cells were washed once 
with warm PBS and examined under Zeiss LSM 510 Confocal/Multiphoton Microscope at 543-
nm excitation with a 560-nm long pass filter at 10X magnification. These images were captured 
digitally.  
 
4-HNE Staining 
BLMVECs grown to 95% confluence in 35-mm dishes (6-well culture plate) on glass 
coverslips and treated with MEM alone, or MEM containing chosen concentrations of hemin 
and/or NBMI or MEM-containing and incubated at 37oC in a humidified environment of 5% 
CO2-95% air. Cover slips were rinsed three times with PBS-T, and fixed with 3.7% 
formaldehyde in PBS for 10 min. at room temperature. The cells were permeabilized in 0.25 % 
Triton X-100 prepared in PBS containing 0.01% Tween-20 (PBS-T) for 5 min. The cells were 
again washed three times with PBS-T, and treated with PBS-T containing 1 % BSA blocking 
buffer for 30 min. at room temperature. Cover slips were then incubated overnight at room 
temperature with the primary antibody [anti-4-hydroxy-2-nonenal (1:150 dilution)] in 1% BSA 
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solution. After rinsing three times with PBS-T, the cells were labeled with secondary AlexaFluor 
488 (1:100 dilution) in 1% BSA in PBS-T for 1 h. Finally, the cells were washed three times 
with PBS-T, mounted, and examined under Zeiss LSM 510 Confocal/Multiphoton Microscope 
powered by Argon-2 laser with 500-550 BP filter. The images were captured digitally and the 
average fluorescent intensity of triplicate samples was determined using ImageJ digital image 
software.   
 
Phospholipase D Activation in Intact ECs 
The activity of PLD in intact BLMVECs was assayed according to our published 
procedures (Secor et al., 2011; Patel et al., 2011; Sherwani et al., 2013). Phosphatidybutanol 
(PBt) formed from the transphosphatidylation reaction between the PLD-hydrolyzed 
phosphatidic acid (PA) and the primary alcohol (1-butanol) in the incubation medium was 
assayed as an index of PLD activity in BLMVECs. BLMVECs grown in 35-mm dishes (5 x 105 
cells/dish) were labeled with [32P]orthophosphate (5 µci/mL) in DMEM phosphate-free medium 
containing 2% (v/v) fetal bovine serum (FBS) for 6-14h. Cells were washed with MEM and 
incubated at 37°C in 1 mL of MEM containing 0.05% (v/v) 1-butanol in absence and presence of 
desired concentrations of hemin for different time points under a humidified 95%air – 5% CO2 
atmosphere. In certain cases, ECs were pre-treated for 1 h or 4 h with selected pharmacological 
inhibitors prior to exposure to hemin. Cells were then either challenged with hemin or co-treated 
with hemin and pharmacological inhibitors for the desired time points. The incubations were 
terminated by the addition of 1 mL methanol:HCl (100:1, v/v). Lipids were extracted according 
to the method of Bligh and Dryer procedure. [32P]-labeled phosphatidylbutanol ([32P]PBt) 
formed from PLD activation and transphosphatidylation reaction, as an index of PLD activity in 
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intact cells, was separated by thin-layer chromatography (TLC). Radioactivity associated with 
the [32P]PBt was quantified by liquid scintillation counting and data were expressed as DPM 
normalized to 106 counts in the total cellular lipid extract or as % of control (vehicle-treated 
cells). 
 
Glutathione (GSH) determination 
Intracellular soluble thiol (GSH) levels were determined using the GSH-Glo assay kit. 
BLMVECs grown up to 90-100% confluence in 96 well plates were pre-treated with MEM alone 
or MEM containing desired concentrations of NBMI or NAC for 2 h under a humidified 95% air 
– 5% CO2 atmosphere according to our published method (Patel et al., 2012). Following 
incubation, cells were treated with hemin and NBMI/NAC for 4 h. intracellular GSH levels were 
determined according to the manufacturer’s recommendations (Promega Corp. Madison, WI). 
 
Phosphatidic Acid Localization Confocal Fluorescence Microscopy 
BLMVECs grown on sterile coverslips in 35-mm dishes were treated with MEM alone 
and MEM containing fluorescent C6:0-18:1 NBD-PA (5 µmol/L) for 24 hours under a humidified 
atmosphere of 95% air – 5% Co2 at 37°C. At the end of the incubation period, cells attached to 
coverslips were washed with 1x PBS, fixed with 3.7% paraformaldehyde for 10 minutes, 
permeabilized with 0.25% triton X-100 in Tris buffer saline Tween-20 (TBST) containing 0.01% 
Tween-20 for 5 minutes, then blocked for 30 minutes with 1% BSA in 0.01% TBST, and 
incubated for 5 minutes at room temperature with 1% (v/v) DAPI in PBS to visualize the nuclei. 
The coverslips with cells were then mounted and viewed under a Zeiss Confocal fluorescence 
microscope at a magnification of 60x, and pictures were captured digitally. 
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Phosphatidic Acid Formation in Intact ECs  
The formation of phosphatidic acid (PA) in intact cells was determined according to our 
published procedure (Patel et al., 2011). At the end of the experiments, treatments of cells were 
terminated by the addition of 1 mL methanol:HCl (100:1, v/v). Lipids were extracted essentially 
according to the method of Bligh and Dyer, as described previously. [32P]-labeled PA formed 
from PLD activation, as an index of PLD activity in intact cells, was separated by TLC. 
Autoradiogram was developed from the TLC plate with [32P]PA separated from other 
phospholipids. Intensity of the radioactivity associated with the [32P]PA was quantified by liquid 
scintillation counting as described previously. 
 
Protein Determination 
Cellular protein was determined by the bicinchoninic acid (BCA) protein assay kit 
(Thermo Scientific, Rockford, Illinois) according to the manufacturer’s recommendations. 
 
Statistical Analysis 
All experiments were done in triplicate. Results were expressed as mean ± standard 
deviation (SD). Statistical analysis of data was done by one-way analysis of variance (ANOVA) 
using the SigmaStat (Jandel Scientific, San Rafael, California). The level of statistical 
significance was taken as P ≤ 0.05. 
 
Preparation of Solutions Containing Pharmacological Agents for Treatment of Cells  
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The stock solutions of lipophilic pharmacological agents including NBMI and FIPI were 
freshly prepared in DMSO and diluted in MEM for treatment of cells. The final DMSO 
concentration in the cell treatment medium was 0.1% (vol/vol) which did not appear to have any 
effect on the outcome of the experiments. All other solutions of water-soluble pharmacological 
compounds were freshly prepared in MEM for treatment of cells. 
 
RESULTS 
Hemin induces PLD activation in dose- and time-dependent fashion in BLMVECs. Iron 
overload and oxidative stress have been reported as the underlying mechanisms of SCD 
complications including inflammation, pain, and vascular dysfunctions (Lucania et al., 2011; 
Machado and Gladwin, 2010; Belcher et al., 2010). Iron and heme are known to cause oxidative 
stress through the generation of ROS (Belcher et al., 2010). Earlier, we have reported that ROS 
and oxidants induce PLD activation in vascular ECs (Parinandi et al., 1999 & 2001). Therefore, 
here we investigated to demonstrate whether hemin would induce PLD activation in BLMVECs. 
As shown in Fig. 3, PLD activity was measured as the extent of formation of [32P] 
phosphatidylbutanol (PBt) in intact cells. Hemin caused significant activation of PLD in dose- 
and time-dependent manner at 50-100 µM concentration at 1 and 4 h (Fig. 4A) as compared to 
that in the control untreated cells. At 4 h of treatment, the hemin-induced activation of PLD was 
3-fold at 50 mM dose as compared to that in the cells treated with 50 µM hemin for 1 h (Fig. 
4A). However, at 100 µM concentration, hemin significantly caused nearly 3.5-fold and 5-fold 
increase in PLD activation in BLMVECs as compared to that in the control untreated cells (Fig. 
4A). When BLMVECs were treated with hemin (10, 25, and 50 µM) for 6 h, a significant and 
dose-dependent induction of PLD activation was observed showing nearly a 15-fold increase in 
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the enzyme activation at 50 µM dose of hemin as compared to the same in the control untreated 
cells (Fig. 4B). A time-course study at 2, 4, and 6 h showed that hemin at 50 µM concentration 
caused a clear time-dependent and significant induction of PLD activation in BLMVECs as 
compared to that in the control untreated cells (Fig. 4C). These results clearly demonstrated that 
hemin induced both dose- and time-dependent activation of PLD in BLMVECs. Furthermore, 50 
µM concentration of hemin and 6 h treatment time were chosen as the optimal dose of hemin and 
treatment time, respectively for PLD activation in BLMVECs in the subsequent experiments of 
this study. 
 
Hemin induces formation of PLD-generated bioactive lipid, PA in dose-dependent fashion 
in BLMVECs. As the previous experiments only demonstrated the hemin-induced activation of 
PLD in both dose- and time-dependent fashion in BLMVECs as measured by the enzyme 
activity in cells, here we investigated hemin-induced formation of PLD-generated bioactive lipid, 
PA in intact BLMVECs. Hemin induced formation of PA in a dose-dependent manner (10-50 
µM) in BLMVECs as determined by the [32P] labeling of cells and TLC analysis of lipids 
following the treatment of cells with hemin as compared to that in the control untreated cells 
(Fig. 5A).  Quantification of radioactivity [32P] in the PA separated by TLC clearly showed 
significant dose-dependent formation of PA in BLMVECs induced by hemin (Fig. 5B). At 50 
µM concentration, hemin at 6 h of treatment, caused ~4.5-fold increase in PA formation in 
BLMVECs. These results showed that hemin induced formation of the PLD-generated bioactive 
lipid, PA in BLMVECs. 
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Antioxidants modulate hemin-induced PLD activation in BLMVECs. Earlier, we have 
reported that antioxidants attenuate oxidant-induced PLD activation in ECs (Parinandi et al., 
1999; Patel et al., 2011). Therefore, here we investigated whether the commonly used 
antioxidants such as vitamin C, propyl gallate, and Trolox (water-soluble form of vitamin E) 
would attenuate hemin-induced PLD activation in BLMVECs. Vitamin C alone (50 and 500 µM 
and 1 mM), in a dose-dependent fashion, induced significant PLD activation at 6 h of treatment 
as compared to the same in the control untreated cells (Fig. 6A). Also, vitamin C caused a 
synergistic effect of significantly enhancing the hemin-induced PLD activation in a dose-
dependent fashion as compared to the same in the hemin-treated cells alone at 6 h of treatment 
(Fig. 6A). On the other hand, the phenolic antioxidant, propyl gallate did not alter hemin-induced 
PLD activation in BLMVECs at 50 and 100 µM doses, but significantly enhanced hemin-
induced activation of the enzyme at 500 µM dose following 6 h of treatment of cells (Fig. 6B). 
However, the water-soluble form of vitamin E (α-tocopherol), an established lipid-soluble 
antioxidant at 500 µM and 1 mM doses, caused significant attenuation  of hemin-induced PLD 
activation at 6 h of treatment in BLMVECs (Fig. 6C). Overall, this study demonstrated that 
among the three tested antioxidants (vitamin C, propyl gallate, and Trolox), only Trolox 
effectively attenuated hemin-induced PLD activation in BLMVECs. 
 
Sulfhydryl agents and thiol-protectants attenuate hemin-induced PLD activation in 
BLMVECs. Oxidants are known to alter or deplete the thiol-redox status in cells (Parinandi et 
al., 1999; Patel et al., 2012). Also, our earlier studies have shown that oxidant-induced PLD 
activation is thiol-redox-regulated and sulfhydryl agents including the thiol-protectants attenuate 
oxidant-induced PLD activation in ECs (Parinandi et al., 1999).  Hence, here we investigated 
21	  
	  
whether the widely used sulfhydryl agents and thiol-protectants would attenuate hemin-induced 
activation of PLD in BLMVECs. The cellular soluble tripeptide thiol, GSH, offered significant 
attenuation of hemin-induced PLD activation at 500 µM and 1 mM doses at 6 h treatment of 
cells as compared to the same in the cells treated with hemin (50 µM) alone (Fig. 7A). On the 
other hand, DTT, another thiol-protectant caused a significant and marked attenuation of hemin-
induced PLD activation in a dose-dependent fashion as compared to the enzyme activation in the 
cells treated with hemin (50 µM) alone for 6 h (Fig. 7B). Although DTT alone at 1 mM dose 
caused PLD activation in BLMVECs at 6 h of exposure, the same caused significant and nearly 
complete attenuation of hemin-induced PLD activation to the extent exhibited by the control 
untreated cells (Fig. 7B). NAC, the commonly used thiol-protectant and thiol enhancer, at both 
50 µM and 1 mM concentrations, failed to cause attenuation of hemin-induced PLD activation in 
BLMVECs at 6 h of treatment, whereas the novel lipid-soluble thiol metal-chelator and 
antioxidant drug, NBMI, offered significant attenuation of hemin-induced activation of PLD in 
cells under identical conditions (Fig. 7C). The two other tested sulfhydryl agents such as L-
cysteine and L-cysteamine even at 1 mM dose were ineffective in causing attenuation of hemin-
induced PLD activation in BLMVECs (Figs. 7D and 7E). Altogether, these results revealed that 
the sulfhydryl agents and thiol protectants including GSH and DTT significantly attenuated 
hemin-induced PLD activation in BLMVECs suggesting the role of cellular thiols in regulation 
of PLD activation by hemin. 
 
Heavy metal-chelating agents and NBMI attenuate hemin-induced PLD activation in 
BLMVECs. Trace metals have been shown to activate phospholipases including PLA2 and PLD 
in vascular ECs (Natarajan et al., 1993; Hagele et al., 2007; Mazerik et al., 2007; Secor et al., 
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2011; Sherwani et al., 2013). Earlier, we have reported that heavy metal chelators and the novel 
lipophilic thiol-redox chelator, NBMI attenuates mercury-induced PLD activation in vascular 
ECs (Secor et al., 2011). Therefore, here we investigated the efficacies of several commonly 
used trace metal chelators including desferal, DMSA, EDTA, PDTC, and NBMI in attenuating 
hemin-induced PLD activation in BLMVECs. PDTC, a dithiocarbamate heavy metal chelator 
was shown to cause synergistically and significantly enhanced hemin-induced PLD activation in 
a dose-dependent fashion in BLMVECs that were treated with hemin (50 µM) for 6 h and the 
chelator drug as compared to the cells treated with hemin alone under identical conditions (Fig. 
8A). NBMI (50 µM) caused significant attenuation of hemin-induced PLD activation in 
BLMVECs as compared to the same in the cells treated with hemin (50 µM) alone for 6 h (Fig. 
8B). DMSA (50 µM and 1 mM) did not appear to be effective in causing attenuation of hemin-
induced PLD activation in BLMVECs (Fig. 8C). EDTA was observed to cause a marginal but 
significant extent of attenuation of hemin-induced PLD activation in BLMVECs (Fig. 8D). 
However, NBMI (50 µM), in comparison with DMSA (50 µM and 1 mM) and EDTA (50 µM 
and 1 mM), exhibited greater and significant efficacy in attenuating hemin-induced PLD 
activation in BLMVECs (Figs. 8C and 8D). However, the widely used iron chelator, desferal, 
offered significant and dose-dependent attenuation hemin-induced PLD activation at 50 µM and 
1 mM doses in BLMVECs treated with hemin (50 µM) for 6 h (Fig. 8E). Furthermore, desferal 
at 1 mM concentration was required to achieve the same and significant extent of attenuation of 
hemin-induced PLD activation in BLMVECs that was caused by NBMI at the dose of 50 µM 
(Fig. 8E). These results clearly demonstrated that among the widely used trace metal chelators 
including EDTA and desferal were less effective than the novel lipophilic thiol-redox heavy 
metal chelator NBMI in attenuating hemin-induced PLD activation. Furthermore, NBMI at 50 
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µM concentration was effective in causing significant and marked attenuation of hemin-induced 
PLD activation in BLMVECs while mM concentrations of EDTA and desferal were required to 
achieve the same. 
 
NBMI attenuates hemin-induced formation of PLD-generated bioactive lipid, PA in 
BLMVECs. The earlier experiments of the current study revealed that NBMI caused a 
significant and marked attenuation of hemin-induced activation of PLD in BLMVECs. Hence, 
here we investigated whether NBMI would attenuate hemin-induced formation of PLD-
generated bioactive lipid, PA, in BLMVECs. As shown in Fig. 9A, the TLC analysis of lipids of 
cells treated with NBMI (50 µM) clearly revealed the attenuation of formation of PA in cells 
treated with hemin (50 µM) for 6 h. Quantification of [32P] radioactivity in the PA of cell 
membrane lipids showed significant and marked attenuation of hemin-induced formation of 
PLD-generated PA in BLMVECs under identical conditions (Fig. 9B). These results 
demonstrated that NBMI was effective in causing attenuation of formation of PLD-generated 
bioactive lipid, PA, in BLMVECs. 
 
PLD-specific inhibitor, FIPI attenuates hemin-induced PLD activation in BLMVECs. 
Earlier, we have reported that the novel PLD-specific inhibitor, FIPI attenuates oxidant and 
heavy metal-induced PLD activation in vascular ECs (Patel et al., 2011; Secor et al., 2011). 
Therefore, here we investigated whether FIPI could attenuate hemin-induced activation of PLD 
in BLMVECs. Our results revealed that the PLD-specific inhibitor, FIPI caused dose-dependent 
(0.1, 0.5, and 1 µM) and significant inhibition of PLD activation in BLMVECs treated with 
hemin (50 µM) for 6 h (Fig. 10). Also, these results confirmed that the PBt formation induced by 
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heme in BLMVECs was mediated by PLD as the PLD-specific inhibitor caused marked 
attenuation of the PLD-mediated PBt formation in cells.  
 
NBMI protects against hemin-induced ROS formation and loss of GSH in BLMVECs. 
Trace metals including iron have been established as crucial players in causing ROS generation 
and loss of thiol-redox and GSH status in vascular ECs (Hagele et al., 2007; Patel et al., 2012). 
Furthermore, we have reported that NBMI attenuates oxidant-induced ROS protection and loss 
of GSH in vascular ECs (Patel et al., 2012). Therefore, here we investigated whether hemin 
would induce ROS generation and loss of GSH in BLMVECs and NBMI would be effective in 
attenuating those outcomes in BLMVECs. As shown in Fig. 11A, hemin (50 µM) caused marked 
increase in ROS (O2.-) generation at 1 h of treatment of BLMVECs as measured by the 
intracellular fluorescence of the O2.--specific intracellular fluorophore which was attenuated by 
NBMI (50 µM). Also, the intracellular GSH analysis revealed that hemin (10, 25, and 50 µM) 
caused a drastic and significant loss of GSH in a dose-dependent fashion in cells following their 
treatment with hemin for 4 h which was significantly attenuated by NBMI (50 µM) (Fig. 11B). 
Moreover these results revealed that basal GSH levels in cells treated with NBMI (50 µM) alone 
were also elevated by 40-fold and the protection against hemin-induced loss of GSH in 
BLMVECs diminished with the increase in the dose of hemin. Overall, these results 
demonstrated that hemin caused ROS generation and loss of cellular GSH in BLMVECs which 
were attenuated by NBMI. 
 
NBMI protects against hemin-induced lipid peroxidation in BLMVECs. Oxidants and trace 
metals have been shown to cause lipid peroxidation which is a hallmark of oxidative stress in 
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vascular ECs (Balla et al., 2005; Maytin et al., 1999; Valko et al., 2005; Jomova and Valko, 
2011). Also, in the earlier experiments of this study, it was revealed that hemin-induced ROS 
production and loss of cellular GSH was attenuated by NBMI. Furthermore, trace metal chelators 
and antioxidants have been shown to protect against oxidant- and metal-induced lipid 
peroxidation (Aviram et al., 1998). Therefore, here we investigated whether (i) hemin would 
induce lipid peroxidation in BLMVECs and (ii) the novel lipophilic thiol-redox chelator and 
antioxidant drug, NBMI would attenuate hemin-induced lipid peroxidation in BLMVECs. The 
confocal immunofluorescence microscopy of formation and intracellular localization of 4-
hydroxy-2-nonenal (4-HNE, an electrophilic product of membrane phospholipid-esterified 
polyunsaturated fatty acid peroxidation) revealed marked and significant induction of lipid 
peroxidation in BLMVECs treated with hemin (50 µM) for 1 h (Figs. 12A and 12B). 
Furthermore, NBMI (50 µM) was observed to significantly and markedly attenuate hemin-
induced lipid peroxidation in BLMVECs. These results demonstrated that the novel lipophilic 
thiol-redox chelator and antioxidant drug was effective in attenuating hemin-induced membrane 
lipid peroxidation in BLMVECs. 
 
NBMI protects against hemin-induced cytotoxicity in BLMVECs. Oxidants and trace metals 
have been shown to cause cytotoxicity in vascular ECs (Secor et al., 2011; Patel et al., 2012). 
Also, the novel lipophilic thiol-redox heavy metal chelator and antioxidant drug has been shown 
to protect against oxidant- and trace metal-induced cytotoxicity in vascular ECs (Secor et al., 
2011; Patel et al., 2012). Therefore, here we investigated whether (i) hemin would cause 
cytotoxicity in BLMVECs and (ii) NBMI would offer protection against hemin-induced 
cytotoxicity in BLMVECs. Hemin (10 and 25 µM) caused alterations in cell morphology (e.g. 
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rounding of cells and loss of shape as an indices of cytotoxicity) at 4 h of treatment which was 
completely protected by NBMI (50 µM) treatment (Fig. 13A). Hemin (50 µM) at 6 h of 
treatment was also observed to cause significant and marked cell membrane damage as 
evidenced by the release of LDH into the medium, which serves as the physiological and 
biochemical index of cytotoxicity (Fig. 13B). NBMI, only at the concentration of 50 mM was 
shown to exhibit protection against hemin-induced LDH release from BLMVECs under identical 
conditions (Fig. 13B). On the contrary, NAC, the common thiol-protector and enhancer appeared 
to significantly enhance hemin-induced LDH release (cytotoxicity) at 50 µM dose and did not 
alter the cytotoxic response at 1 mM dose whereas NBMI at 50 µM dose exhibited significant 
and marked protection against hemin-induced LDH release from BLMVECs (Fig. 13C). These 
results clearly demonstrated that hemin induced cytotoxicity in BLMVECs, which was protected 
by the novel thiol-redox chelator and antioxidant drug, NBMI but not by the widely used thiol-
protector and enhancer, NAC. 
 
PLD-specific inhibitor, FIPI protects against hemin-induced cytotoxicity in BLMVECs. 
Our earlier studies have shown that the novel PLD-specific inhibitor, FIPI nor only attenuates 
oxidant and trace metal-induced PLD activation but also protects against cytotoxicity induced by 
oxidants and trace metals in vascular endothelial cells (Secor et al., 2011; Patel et al., 2011). 
Also, in the earlier experiments of the current study demonstrated that FIPI significantly 
attenuated hemin-induced PLD activation in BLMVECs. Therefore, here we investigated 
whether the PLD-specific inhibitor, FIPI, would protect against hemin-induced cytotoxicity in 
BLMVECs. Hemin (50 µM) caused marked alterations of cell morphology (as an index of 
cytotoxicity) in BLMVECs at 4 h of treatment and FIPI (0.1 and 0.5 µM) distinctly protected 
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against hemin-induced alterations of cell morphology (Fig. 14A). Additionally, hemin (50 µM) 
at 6 h of treatment caused significant cell membrane damage and release of intracellular LDH 
into the medium as compared to that in the control untreated cells that was significantly 
attenuated by FIPI (0.1, 0.5, and 1.0 µM) in a dose-dependent fashion as compared to the cells 
treated with hemin alone under identical conditions (Fig. 14B). These results clearly 
demonstrated that the PLD-specific inhibitor FIPI protected against hemin-induced cytotoxicity 
in BLMVECs confirming the role of PLD therein.  
 
 
 
 
 
 
 
 
DISCUSSION 
 The present study revealed that the hemoglobin degradation product, hemin that 
accumulates during SCD crisis caused ROS generation, oxidative stress, loss of cellular GSH 
redox status, activation of PLD, and formation of intracellular bioactive lipid signal mediator 
(PA) leading to cytotoxicity in cultured lung vascular EC model. The hemin-induced EC damage 
was protected by certain sulfhydryl agents, thiol-protectants, and especially by the novel 
synthetic thiol-redox heavy metal chelator and antioxidant drug, NBMI with a greater efficacy. 
Furthermore, the current study also demonstrated that the novel lipophilic PLD-specific 
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pharmacological inhibitor, FIPI, attenuated hemin-induced PLD activation and protected against 
hemin-induced cytotoxicity in BLMVECs suggesting that hemin-induced cytotoxicity in ECs 
was mediated by the redox-regulated PLD lipid signaling through the generation and action of 
the bioactive lipid signal mediator, PA (Fig. 15). 
 
 PLD is a ubiquitous enzyme present in the mammalian cells including the vascular ECs 
in two different isoforms as PLD1 and PLD2 (Cummings et al., 2002; Parinandi et al., 2001). 
Although the cellular localization of both isoforms is not known precisely, PLD1 has been 
localized predominantly in the nucleus whereas PLD2 has been detected in both cytosolic and 
nuclear compartments of the vascular ECs (Parinandi unpublished work). PLD1 is known to be 
activated by co-factors including the adenosine 5’-diphosphate ribosylation factor (ARF) and 
phosphatidylinositol bisphosphate (PIP2), whereas PLD2 is activated by PIP2 (Parinandi et al., 
2001; Natarajan et al., 2001). Protein kinases such as the protein kinase C (PKC), protein 
tyrosine kinases (PTyKs) including Src kinase, and the mitogen-activated protein kinases 
(MAPKs) including the p38 MAPK and extracellular signal-regulated kinases (ERK1/2) have 
been identified to regulate the activation of PLD during conditions of oxidative stress in vascular 
ECs (Parinandi et al., 2001; Natarajan et al., 2001; Secor et al., 2011). Also, the small G proteins 
have been shown to regulate the activity of cellular PLDs (Parinandi et al., 2001). In addition, 
PLD in vascular ECs has been shown to be activated by oxidants, heavy metals like mercury, and 
perturbations of the thiol-redox (GSH) status in vascular ECs (Natarajan et al., 2001; Parinandi et 
al., 1999; Secor et al., 2011; Patel et al., 2011). Along these lines, the current investigation 
clearly demonstrated the oxidant-mediated and thiol-redox-regulated activation of PLD and 
generation of the bioactive lipid signal mediator (PA) in BLMVECs exposed to hemin, the 
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regulation of PLD by other signaling protein kinases such as PKC, PTyKs, and MAPKs and 
small G proteins has not been ruled out. The current work also suggests that heme-iron such as 
hemin can possibly activate PLD during SCD iron overload leading to lipid signaling cascades in 
vascular ECs mediated by PLD-generated bioactive lipid signal mediator, PA. 
 
 PLD has emerged as an important cellular signaling phospholipase which mediates 
several cellular functions such as mitogenesis, cytoskeletal regulation, and secretion in several 
mammalian cells including the vascular ECs (Parinandi et al., 2011). The PLD-generated 
bioactive lipid signal mediator, PA, can further undergo metabolic transformation into more 
potent bioactive lipid signal mediators such as the lysophosphatidic acid (LPA; generated by 
either phospholipase A1 or A2) and diacylglycerol (DAG; generated by lipid phosphate 
phosphohydrolase) (Parinandi et al., 2011). All these bioactive lipid signal mediators generated 
by PLD are potent signal mediators that affect the target proteins leading to 
modulation/alteration of cellular functions such as cytoskeletal reorganization, cellular adhesion, 
mitogenesis, and cell viability. DAG is a known endogenous activator of PKC which mediates 
several cellular signaling cascades. Also, the signaling actions of LPA are mediated by specific 
LPA receptors in cells. Recently, we have reported that mercury-induced cytotoxicity in vascular 
ECs has been regulated by PLD activation through ROS production, oxidative stress, thiol-redox 
dysregulation, and generation of the bioactive lipid signal mediator, PA (Patel et al., 2011; Secor 
et al., 2011). We have also reported that PLD regulates the oxidant-induced EC barrier 
dysfunction and vascular endothelial permeability suggesting that PLD plays a crucial role in 
mediating the vascular leakiness through oxidative stress mechanism (Usatyuk et al., 2013). 
These studies support the current findings that hemin-induced PLD through generation and 
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actions of the bioactive lipid signal mediators (PA, LPA, and DAG) might be responsible for the 
hemin-induced cytotoxicity in BLMVECs through oxidant regulation. Although no attempts 
were made in the current study to determine the levels of LPA and DAG in BLMVECs during 
hemin exposure, it could be surmised that hemin could induce the formation of these bioactive 
lipid signal mediators that are capable of mediating adverse effects of hemin in lung vascular 
ECs as the underlying mechanisms of pulmonary hypertension in SCD. Also, this signifies the 
pressing need for identification and determination of the PLD-generated bioactive lipid 
mediators as biomarkers of vascular endothelial dysfunction in hemoglobinopathies such as SCD 
with iron overload. 
 
 Hemolysis has been shown to cause release of Hb into extracellular regions causing 
complications in patients through the release of hemin from Hb (Schaer et al., 2013). Hemin is a 
potent signal mediator that causes damaging effects in pathological conditions including SCD. 
Hemin when administered into sickle mice has been shown to cause acute chest syndrome, the 
hallmark of SCD (Ghosh et al., 2013). Hemin release has been shown to arise from HbS 
denaturation which accumulates up to 3- to 5-fold in SCD patients suggesting the erythrocyte 
damage caused by hemin in SCD condition (Liu et al., 1988). Hemin accumulation in SCD 
pathology has also been suggested to cause erythrocyte damage (Shaklai et al., 1985). Hemin by 
nature is hydrophobic/lipophilic and tightly associated with the cell membrane (Belcher et al., 
2010). Upon reaction with hydrogen peroxide, hemin releases the free redox-active iron which 
mediates the generation of ROS that cause oxidative stress through peroxidation of membrane 
lipids and oxidative degradation of proteins and nucleic acids leading to adverse effects on cells 
under pathophysiological conditions of SCD (Belcher et al., 2010). Thus, hemin is a potent 
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oxidant that causes damage of cells including the vascular ECs as witnessed in the current study. 
Although, the exact mechanism of ROS generation induced by hemin in BLMVECs in the 
current study was not established, the role of endothelial NAD[P]H oxidase in hemin-induced 
ROS generation in lung microvascular ECs is not ruled out since the role of NAD[P]H oxidase 
has been shown in ROS generation in lung ECs has been established (Parinandi et al., 2003). 
Hence, there could be substantial generation of hydrogen peroxide in BLMVECs exposed to 
hemin which further could have contributed to the release of free iron capable of catalyzing the 
Fenton reaction in the cells. Thus, the role of hemin-generated free iron in causing oxidative 
stress in lung vascular ECs appears to be possible.  
 
 Pulmonary hypertension, a common SCD complication is being identified as a major risk 
factor for mortality among adult patients (Machado and Gladwin, 2005). Although several 
causative factors have been addressed in the pathogenesis of SCD pulmonary hypertension, the 
role of iron, ROS, oxidative stress and redox signaling leading to lung vascular damage have 
been emerging (Wong et al., 2012 & 2013; Touyz 2004). In spite of lack of thorough 
understanding of the specific mechanism(s) of pulmonary hypertension, iron-mediated protein 
carbonylation has been suggested to play a crucial role in the pathogenesis of pulmonary 
hypertension (Wong et al., 2013). The NAD[P]H oxidase family of enzymes (Nox) present in the 
lung vessels have been implicated as the crucial enzymes responsible for ROS generation 
responsible for pulmonary hypertension (Freund-Michel et al., 2013). Along these lines it is 
surmised that hemin-induced ROS and oxidative stress in lung vascular endothelium could be 
responsible for the pathogenesis of pulmonary hypertension in SCD patients.  
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 Iron, whether free iron or Fe3+-heme (hematin), appears as the upstream player to induce 
ROS generation, oxidative stress, and thiol-redox dysregulation which trigger the down-stream 
signaling events such as PLD activation and bioactive lipid mediator generation that cause lung 
vascular endothelial dysfunction and damage. Antioxidants that neutralize ROS and diminish 
oxidative stress have been recommended as therapeutic agents for pulmonary hypertension 
(Wong et al., 2013). On the other, iron chelation has been shown to decrease remodeling of 
pulmonary vasculature indicating that iron-mediated ROS play a mechanistic role in the 
pathogenesis of pulmonary hypertension (Wong et al., 2012). Therefore, iron chelators appear as 
promising therapeutic agents in the treatment of SCD pulmonary hypertension. Although the iron 
chelators such as deferasirox (DFRA), deferoxamine, and deferiprone have been used for iron 
chelation therapy in SCD patients, these chelators are either not completely efficacious or their 
safety is questionable (Vlachaki et al., 2013; Lucania et al., 2011; Maggio, 2007). The current 
study clearly demonstrated that the novel lipophilic thiol-redox heavy metal chelator and 
antioxidant drug, NBMI, effectively attenuated hemin-induced ROS production, oxidative stress, 
oxidant lipid signaling, and cytotoxicity in lung vascular ECs (Fig. 15). These results emphasized 
the advantages of using NBMI as the iron chelator of drug of choice to treat iron overload and 
iron-mediated SCD complications including pulmonary hypertension for reasons such as (1) 
NBMI is lipophilic and non-toxic and unlike the water-soluble iron chelator drugs that are 
commonly used in clinical settings, NBMI can reach the membrane lipid targets protecting 
against iron-induced oxidative stress by complexing with iron and rendering it catalytically 
inactive; (2) NBMI has a thiol-stabilizing action and therefore will protect against the loss or 
dysregulation of thiol-redox status induced by iron; and (3) NBMI also exhibits antioxidant 
actions and thus protects cells against oxidative stress including lipid peroxidation.  
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NBMI has dicarboxybenzoate moiety which is naturally present in fruits and bound to 
two cysteamines (Secor et al., 2011). Hence, it is expected that NBMI can act as both a trace 
metal (iron) chelator and free radical scavenger. The heavy metal-chelating ability of NBMI has 
been reported (Secor et al., 2011). Therefore, the EC protective action of NBMI against the 
hemin-induced cytotoxicity as demonstrated in the current study could have been mediated by 
the ability of NBMI to stabilize or protect the cellular thiol redox, attenuate oxidative stress, and 
chelating iron. Moreover, the lipophilicity/hydrophobicity of NBMI could have been 
advantageous for compound to precisely localize in the hydrophobic phospholipid domains of 
the EC membrane where the redox signaling events such as the PLD-generated bioactive lipids 
could operate leading to the hemin-induced cytotoxicity of lung microvascular ECs. The novel 
lipophilic bifunctional chelating drug, NBMI, with thiol-redox antioxidant action appears to 
immensely impact the progressing therapies effective for the treatment of iron overload in SCD. 
Currently available treatments for iron toxicity and overload only include the water-soluble iron 
chelators and low-molecular weight thiols. On the other hand, the lipophilic drugs including 
NBMI and FIPI are promising to be more efficacious to offer protection against iron-induced 
oxidative stress and cell damage, especially those are encountered in SCD through their actions 
in the hydrophobic lipid bilayer of the cellular membranes that hosts the cellular redox reactions, 
phospholipid hydrolysis, and oxidant-mediated signaling cascades. Therefore, NBMI appears to 
be a promising dual action drug capable of iron chelation and antioxidant action that can be used 
in iron-induced SCD complications including pulmonary hypertension. 
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LIST OF ABBREVIATIONS 
4-HNE: 4-hydroxy-2-nonenal 
ANOVA: analysis of variance 
BCA: bicinchoninic acid 
BLMVECs: bovine lung microvascular endothelial cells 
DAG: diacylglycerol 
DAPI: 4’,6-diamindino-2-phenylindole dihydrochloride 
DFRA: deferasirox 
DHE: dihydroethidium 
DMEM: Dulbecco’s modified Eagle medium 
DMSA: meso-dimercaptosuccinic acid 
DMSO: dimethylsulfoxide 
DTT: dithiothreitol 
ECs: endothelial cells 
EDTA: ethylenediaminetetraacetic acid 
ERK: extracellular signal-regulated kinase 
FBS: fetal bovine serum 
FIPI: 5-fluoro-2-indolyl des-chlorohalopemide hydrochloride hydrate 
GSH: glutathione 
Hb: hemoglobin 
HbA: adult hemoglobin 
HbC: hemoglobin C 
HbS: hemoglobin S 
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LDH: lactate dehydrogenase 
LPA: lysophosphatidic acid 
MAPK: mitogen-activated protein kinase 
MEM: minimal essential medium 
metHb: methemoglobin 
MTT: 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
NAC: N-acetyl-L-cysteine 
NBMI: N,N’-bis-2-mercaptoethyl isophthalamide 
Nox: NAD[P]H oxidase 
PA: phosphatidic acid 
PBS: phosphate-buffered saline 
PBS-T: phosphate-buffered saline-Tween-20 
PBt: phosphatidylbutanol 
PDTC: pyrrolidine dithiocarbamate 
PIP2: phosphatidylinositol bisphosphate 
PKC: protein kinase C 
PLA2: phospholipase A2 
PLD: phospholipase D 
PTyKs: protein tyrosine kinases 
RBCs: red blood cells 
ROS: reactive oxygen species 
SCD: sickle cell disease 
TLC: thin-layer chromatography 
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Figure 1 
Figure1: Chemical structure of Hemin and Hematin. 
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Figure 2: Chemical structure of the novel synthetic lipophilic thiol-redox 
heavy metal chelator [N,N'-bis-2-mercaptoethyl isophthalamide (NBMI), 
pharmacological compounds N-acetyl-L-cysteine (NAC), meso-2,3-
dimercaptosuccinic acid (DMSA), and antioxidant glutathione (GSH). 
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Figure 3 
Figure 3: PLD catalyzes the hydrolysis of head group of 
membrane phospholipids (e.g. phosphatidylcholine, PC) and 
generates free head group (e.g. choline) and phosphatidic acid 
(PA). PLD is also capable of using primary alcohols (e.g. 
ethanol and butanol) to form phosphatidylalcohols (e.g. 
phosphatidylethanol, PEt and phosphatidylbutanol, PBt). PA 
can also be metabolized by cells into other bioactive lipids 
such as diacylglycerol (DAG) and lysophosphatidic acid (LPA). 
The bioactive lipids such as PA, DAG, and LPA cause cellular 
signaling. 
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